Title: Journal Club
1Journal Club
- 17th March, 2003
- Dr Ramon Varcoe
2Which rectal cancers should
be treated with
PREOPERATIVE RADIATION ?
3BackgroundThere is evidence to support the
rationale of giving radiotherapy before surgery
while the SI is mobile and not fixed in the
pelvis with adhesions..
- Swedish Rectal Cancer Trial. NEJM. 1997
- 1168 patients with rectal cancer stages I-III
- Preop short course RT improved LR (11 vs 27) and
survival (58 vs 48) - Camma etal. (meta-analysis) JAMA. 2000
- 14 studies/6426 patients
- Improved LR (OR 0.49/Plt0.001) and overall
mortality (OR 0.84/P0.03) with PRT
4Background
- Camma etal. (meta-analysis) JAMA 2000
- 14 studies, 6426 patients
- Early rectal cancers (T1/T2) show no benefit from
preop radiation therapy - Lopez-Kostner etal. (Cleveland) Surgery 1998
- Upper third rectal cancer behave like colon
cancer in terms of LR and disease profile - Marsh etal. (Manchester) DCR 1994
- 284 patients. Prospective, randomized controlled
trial - Locally advanced (T4) low rectal cancers show
reduced LR with preop RT but overall survival is
similar
5PROBLEMS
- Inaccurate PREOPERATIVE STAGING
- (ERUS is most sensitive for bowel wall invasion,
86 by Napoleon etal BJS 1991) - At the time of publication all trials that
demonstrate benefits of PreopRT do not describe
formal TME. - Most Trials therefore have LR 25-50 instead of
the expected 4-9 with TME - Nb.The Dutch Colorectal Cancer Group Trial has
since been published using TME and confirming the
survival benefits seen in the Swedish trial
6Preoperative Radiotherapy Improves Survival for
Patients Undergoing Total Mesorectal Excision for
Stage T3 Low Rectal Cancers
- by C.Delaney, I.Lavery, A.Brenner, J.Hammel,
A.Senagore, R.Noone and V.Fazio - Cleveland Clinic, Ohio, USA
- Annals of Surgery
- 236(2), 2002, 203-7
7(No Transcript)
8OBJECTIVE
- Examine effects of Preoperative Radiotherapy
(PRT) - ON
- T3 low rectal cancers
- Undergoing TME rectal excision
9STUDY DESIGN
- Retrospective
- 1980-2001
- Adenocarcinoma of rectum lt8cm from AV
- Undergoing Anterior Resection or APR
- T3 tumours on histology
- T3 on ERUS (cohort group)
- Excluded if
- Proven metastatic disease
- Had Post-op radiotherapy or chemotherapy
10STUDY DESIGN
- Long course radiotherapy
- 40-50 Gy over 4-6 weeks then surgery 4-6 weeks
later - Total mesorectal excision (TME) surgery
- Excision of the mesorectum with its investing
fascial layer preserving the pre-sacral autonomic
nerves and Denonvilliers fascia
11RESULTS
- 259 patients
- 92 had PRT, 167 did not
- Matched with similar but not identical
demographic data (see table 1), similar tumour
details and surgical procedures - An ultrasound control group was incorporated to
attempt to nullify the potential for histological
down staging with PRT
12The treatment group is significantly younger
13Overall survival benefit after treatment with PRT
Cancer specific survival benefit also dominated
by node negative tumours
Local recurrence rates were also marginally
reduced with PRT
14Overall survival is significantly improved by
giving radiation in this 2-5 cm group
Show me the money
In the same group cancer specific survival is
also significantly improved
15Again overall survival is improved with PRT,
driven by the node negative group
16CONCLUSIONS
- T3 tumours less than 8 cm from AV should be
treated with PRT - Especially node negative tumours
- Especially tumours 2-5 cm
- Insufficient evidence to exclude subgroups of T3
tumours from treatment at this stage
17Trial strengths
- Two established surgeons
- Standardised technique of TME
- Large numbers
18Problems with this trial
- Retrospective
- 38 of the 92 that had PRT also had simultaneous
chemotherapy (interestingly they had a worse OS
53.2 vs 71.0) - Downstaging effect of PRT may affect histology
- This potential histology inaccuracy creates a
crucial flaw in the study design
19The next question is "Do we use long course or
short course radiation ?"
20The Trans-Tasman Radiation Oncology Group (TROG)
TrialA Randomised Trial of Preoperative
Radiotherapy for Stage T3 Adenocarcinoma of
Rectum
21TROG trial
- Commenced July 2001
- Multicentre (17 so far)
- More than 100 patients recruited
22The End